Increased expression of NAPDH oxidase 4 in systemic sclerosis dermal fibroblasts: regulation by transforming growth factor β.
Increased expression of NAPDH oxidase 4 in systemic sclerosis dermal fibroblasts: regulation by transforming growth factor β.
复制标题
DOI:
10.1002/art.39242
复制
发表时间:
2015-10
期刊:
影响因子:
--
通讯作者:
Jiménez SA
中科院分区:
文献类型:
--
作者:
Piera-Velazquez S;Makul A;Jiménez SA
Systemic Sclerosis (SSc) is characterized by severe and often progressive skin and multiple internal organ fibrosis. The mechanisms responsible for these alterations remain obscure, although excessive ROS-mediated oxidative stress has been implicated. NOX4 is one of seven NADPH oxidase isoforms responsible for ROS generation. Here, we examined NOX4 expression in SSc skin and cultured dermal fibroblasts and its regulation by TGF-β. NOX4 was assessed in normal and SSc skin employing immunohistology, and in normal and SSc cultured dermal fibroblasts by quantitative PCR, fluorescence microscopy and Western blots. ROS levels were assessed by fluorescence measurements of H2O2 production. The TGF-β signaling involved in NOX4 stimulation was studied employing specific kinase inhibitors. NOX4 inhibition/downregulation was induced with a selective NOX4 small molecule inhibitor and NOX4 siRNA. In contrast with normal skin SSc skin fibroblasts showed intense NOX4 staining. Cultured SSc fibroblasts displayed increased NOX4 expression. TGF-β1 caused potent NOX4 protein and mRNA stimulation in normal and SSc fibroblasts mediated by PKC-δ and SMAD2/3 pathways. NOX4 knockdown in SSc fibroblasts reduced ROS production and lowered collagen I expression. NOX4 expression and production are constitutively elevated in SSc skin and cultured SSc dermal fibroblasts. TGF-β1 stimulates NOX4 expression in normal and SSc fibroblasts through PKC-δ and Smad2/3 signaling pathways. A small molecule NOX4 inhibitor decreased fibroblast collagen and fibronectin production and NOX4 siRNA knockdown reduced SSc fibroblast ROS and collagen production. These results demonstrate NOX4 involvement in SSc-associated fibrosis and suggest NOX4 inhibitors as novel therapeutic approaches for SSc.